Eutilex Co.,Ltd. Logo

Eutilex Co.,Ltd.

Develops T-cell and antibody immunotherapies for cancer and autoimmune diseases.

263050 | KO

Overview

Corporate Details

ISIN(s):
KR7263050007
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of breakthrough immunotherapeutics for incurable diseases, particularly cancer and autoimmune disorders. The company's core activities are centered around three proprietary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Its pipeline includes adoptive T-cell therapies, such as 4-1BB cytotoxic T-lymphocytes (CTL), and immunomodulatory antibody therapeutics designed to act as immune checkpoint activators, stimulating T-cells to enhance anti-tumor immune responses. Eutilex's approach is based on selecting novel targets that effectively enhance or suppress human immune functions to treat diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-06-30 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.0 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.0 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.3 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.3 KB
2025-05-22 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 116.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 959.6 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.7 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 112.9 KB
2025-05-08 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 10.1 KB

Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eutilex Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America
REFR

Talk to a Data Expert

Have a question? We'll get back to you promptly.